Little research has been done to test the usefulness of metastasis-associated protein 1 (MTA1) as a prognostic marker for non-small cell lung cancer (NSCLC). In this study, we investigated MTA1 expression and its prognostic value for NSCLC. Methods: NSCLC surgical tissue samples were taken from 100 patients with NSCLC who had been followed up for more than 2 years. The expression of MTA1 protein was evaluated by immunohistochemistry, and the correlations between the expression of MTA1 and clinical features and the prognosis were analyzed. The difference of MTA1 protein expression between NSCLCs and their adjacent nonneoplastic lung tissues was analyzed in a tissue microarray. The change of MTA1 mRNA expression and protein expression after RNA interference (RNAi) was detected by realtime polymerase chain reaction, Western blot, and immunocytochemistry in NSCLC cell line 95D. Results: Overexpression of MTA1 (immunoreactivity scoring Ͼ4) was shown in 61.0% of the NSCLC cases but only in 9.4% of their adjacent nonneoplastic lung tissues (p Ͻ 0.001). The MTA1 expression level was correlated with lymph node metastasis (p ϭ 0.013) and clinical stage (p ϭ 0.002). Survival analysis showed that the MTA1 overexpression group had a significantly shorter overall survival time than the MTA1 downexpression group (p ϭ 0.003). However, multivariate analysis showed that MTA1 expression was not a significant and independent prognostic parameter for patients with NSCLC. After RNAi, the 95D cells exhibit consistent reduction in MTA1 mRNA expression and MTA1 protein expression. Conclusion: MTA1 protein expression is associated with tumor progression and clinical outcome in patients with NSCLC. Further molecular, cellular, and animal model studies on MTA1 gene will provide new clues for exploring the mechanism of carcinogenesis and tumor progression in patients with NSCLC.
L ung cancer is a serious threat to human health and life and is known as world's leading killer. Both the morbidity and mortality of lung cancer head the list in the malignant tumors. With the aggravation of air pollution, the morbidity of lung cancer showed a marked increase. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancer. Despite progresses in diagnosis and therapy has been made recently, the prognosis of lung cancer remains very poor, and the 5-year cumulative survival rate is less than 15%. Cancer metastasis is the major cause of death in patients with lung cancer.
Metastasis is a complex disease involving a series of events that includes stimulation or repression of numerous gene products in a coordinate manner, resulting in the invasion of neoplastic cells and detachment from the primary tumors, penetration into blood and lymphatics, arrest by adhesion at distant sites, extravasation, induction of angiogenesis, evasion of host antitumor responses, and growth at metastatic sites. 1 The role of metastasis-associated proteins (MTAs) family of coregulators in transcriptional programs has aroused wide concern recently. 2,3 MTA are integral parts of nucleosome remodeling and histone deacetylation (NuRD) complexes. 4, 5 MTA family members exist in distinct NuRD complexes, 6 and functional redundancy is lacking among MTA family members. MTA proteins regulate divergent cellular pathways, including hormonal action, epithelial-to-mesenchymal transitions, differentiation, protein stability and development, and cell fate programs by modifying the acetylation status of crucial target genes. 2 MTA1, the founding member of the MTA family of genes, was originally identified through differential screening of a cDNA library from rat metastatic breast tumors. 7 Subsequent studies found a widespread upregulation of MTA1 in human tumors. 8 MTA1 is closely associated with the carcinogenesis and metastasis of many human carcinomas, including endometrial adenocarcinomas, gastrointestinal carcinoids, colorectal carcinoma and hepatocellular carcinoma, esophageal squamous cell carcinoma, prostate cancer, thymomas, etc. 9 -15 Recently, researches 16, 17 have suggested that MTA1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma or breast cancer. However, the potential prognostic relevance of MTA1 expression in NSCLC has not yet been investigated.
In this study, we attempted to investigate the expression of MTA1 in NSCLC using immunohistochemical analysis, identify its relationship with clinicopathological features, and evaluate its prognostic value in respect of survival in patients with NSCLC.
PATIENTS AND METHODS

Patients and Tissue Samples
A total of 100 patients with NSCLC, who had undergone routine surgery at Nangfang Hospital, Guangzhou City, Guangdong Province, China from January 2002 and December 2006, were enrolled in our retrospective study. They were not pretreated with radiotherapy or chemotherapy before surgery. The patients were followed up for a median period of 25.1 months (range, 1.4 -59.3 months) after operation, and their complete clinical data were collected. All NSCLC samples taken from the 100 patients were fixed in 10% formalin, embedded in paraffin, sectioned consecutively at 4 m, and stained by hematoxylin and eosin. All tumors were classified according to World Health Organization classification, 18 and the staging of the tumor was done according to the international staging system. 19 The study was approved by the Ethical Committee of Nanfang Hospital of Southern Medical University, and written informed consent was obtained from each patient. All samples were made anonymous, and none of the researchers conducting the experiments in the study had access to clinicopathological data.
The tissue microarray consisted of 64 NSCLC samples, and their adjacent nonneoplastic lung tissues was obtained from Outdo Biotech CO. Ltd. (ShangHai, China).
Immunohistochemical Staining
The sections were deparaffinized and rehydrated, and endogenous peroxidase was inhibited with 0.3% H 2 O 2 methanol. For antigen retrieval, slides were boiled in 0.01 M, pH 6.0 sodium citrate buffer for 15 minutes in a microwave oven. After blocked with the 5% normal goat serum, primary antibody (goat anti-MTA1, Santa Cruz Biotechnology, Santa Cruz, CA) in blocking buffer (1:150) was applied, and the slides were incubated at 4°C overnight. After incubation with biotinylated secondary antisera, the streptavidin-biotin complex/horseradish peroxidase was applied. Finally, the visualization signal was developed with 3,3Ј-diaminobenzidine tetrahydrochloride, and the slides were counterstained in hematoxylin. Negative controls had the antibody replaced by phosphate-buffered saline (PBS).
Evaluation of Immunohistochemical Staining
The nuclear staining of MTA1 in tumor tissue was scored by applying a semiquantitative immunoreactivity scoring (IRS) system, as reported elsewhere. 20 Concomitant cytoplasmic staining was not counted. Category A documented the intensity of immunostaining as 0 (no immunostaining), 1 (weak immunostaining), 2 (moderate immunostaining), and 3 (strong immunostaining). Category B documented the percentage of immunoreactive cells as 0 (none), 1 (Ͻ10%), 2 (10 -50%), 3 (51-80%), and 4 (Ͼ80%). Multiplication of categories A and B resulted in an IRS ranging from 0 to 12 (negative[IRS, 0] versus weak [IRS, [1] [2] [3] [4] versus moderate [IRS, [5] [6] [7] [8] versus strong [IRS, 9 -12] )for each tumor. Both percent positivity of cells and staining intensity were decided in a double-blinded manner. Interobserver and intraobserver variability was negligible. Tumors with moderate or strong expression (IRS Ͼ4) were considered to show MTA1 overexpression, whereas tumors with negative or weak expression (IRS Յ4) were considered to show MTA1 downexpression.
Cell Lines and Cell Culture Conditions
The human lung cancer cell line 95D was purchased from the cell bank of Chinese Academy of Sciences and cultured in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin in a 5% CO 2 humidified atmosphere at 37°C.
MTA1 Small Interfering RNA Transfection
Cells were seeded onto a 6-well plate 16 hours before transfection. In each well, 10 L of MTA1 small interfering RNA (GACCCTGCTGGCAGATAAA) 21 or empty vector and 10 L of Lipofectamine 2000 (Invitrogen) were added to Opti-MEM and mixed gently and added to the plates. The plate was incubated for 48 hours until it was ready for further assay.
Real-Time PCR Analysis for MTA1 mRNA
Total RNA from cells was extracted using Trizol reagent (Invitrogen) according to the manufacturer's instructions. DNase-I-treated total RNA (ϳ1g) was used as starting material, to which 1 L (1g/l) of oligo (dT) primer was added, and diethypyrocarbonate-treated water was added to the total volume of 11 L. The RNA mixes were heated at 65°C for 5 minutes and then chilled on ice. To each RNA mix, the following components were added: 4 L of 5ϫ first-strand buffer, 2 L of 0.1 M dithiothreitol, 1 L of 10 mM deoxyribonucleotide triphosphate, and 1 L of ribonuclease inhibitor. The samples were incubated at 42°C for 2 minutes, followed by addition of 200 U of Superscript II and incubation at 42°C for 50 minutes. The reaction was inactivated at 70°C for 5 minutes. The following primers were used for amplification of MTA1: sense primer, 5Ј-GAAATATG-GTGGCTTGAAAAT-3Ј and antisense primer, 5Ј-ACTTTG-GTGGGGTAGGACTTC-3Ј. ␤-actin was amplified as an internal control using sense primer, 5Ј-CGTGGGCCGC-CCTAGGCA-CCA-3Ј and antisense primer, 5Ј-TTGGCT-TAGGGTTCAGGGGGG-3Ј. Real-time PCR was performed using SYBR Green PCR kit(s) following the manufacturer's protocol. The annealing temperature was 56°C for 40 seconds. The relative quantification is determined using the 2 Ϫ⌬⌬Ct method. 22 Protein lysates were resolved on 6% sodium dodecyl sulfate polyacrylamide gel, electrotransferred to polyvinylidene fluoride membranes (Immobilon P; Millipore, Bedford, MA), and blocked in 5% nonfat dry milk in Tris-buffered saline, pH 7.5 (100 mM NaCl, 50 mM Tris, and 0.1% Tween-20). Membranes were immunoblotted overnight at 4°C with anti-MTA1 polyclonal antibody (Santa Cruz Biotechnology, SantaCruz, CA), and anti-␤actin antibody (Santa Cruz Biotechnology), followed by their respective horseradish peroxidase-conjugated secondary antibodies. Signals were detected by enhanced chemiluminescence (Pierce, Rockford, IL).
Statistical Analyses
Statistical analysis was performed using SPSS 13.0 software. A 2 test was used to analyze the MTA1 protein expression in different groups. Survival curves were calculated using the Kaplan-Meier method and were analyzed using the log-rank test. The prognostic significance of various factors was also determined by univariate and multivariate analyses using the Cox proportional hazard regression model. The statistical significance was defined as p Ͻ 0.05.
RESULTS
Expression of MTA1 in NSCLC and Adjacent Nonneoplastic Lung Tissues
On the tissue microarray, MTA1 was overexpressed in 39 (61.0%) NSCLCs but only in six (9.4%) adjacent nonneoplastic lung tissues (p Ͻ 0.001). The normal alveolar epithelium exhibited negative or weak expression of MTA1; however, the normal bronchiolar epithelium exhibited moderate or strong expression, Figure 1 . The patterns of MTA1 expression were mixed nuclear/cytoplasmic staining. Similarly, of the 100 surgical specimens of NSCLC, 67 (67.0%) exhibited overexpression of MTA1, and downexpression was found in the other 33 (33.0%) cases, Figure 2 .
Expression of MTA1 in NSCLC Cell Lines
To investigate whether MTA1 protein expression is correlated with mRNA expression, the endogenous MTA1 gene silencing in 95D cell was performed through a small interfering RNA knockdown technique, and the expression of MTA1 mRNA, and MTA1 protein were detected by real-time PCR, Western blot, and immunocytochemistry, respectively. Results showed that both MTA1 protein expression and MTA1 mRNA expression were significantly decreased in the transfected 95D cell, Figure 3 . Table 1 shows the correlation of MTA1 protein expression with clinical and pathologic features. MTA1 protein level in stage III/IV NSCLC was significantly higher than the level in stage I/II NSCLC (p ϭ 0.002). Higher MTA1 expression levels were associated with lymph node metastasis (p ϭ 0.013). There was no correlation between MTA1 ex-pression level and age, gender, histopathologic type, histologic differentiation, local advance, or distant metastasis.
Correlation Between MTA1 Expression and Clinicopathological Features
Evaluating the Prognostic Relevance of MTA1 Expression or Different Clinicopathological Factors in NSCLC Univariate Analysis
As the patients in this cohort had variable follow-up times between 1.4 and 59.3 months, the Cox proportional hazards model and single-parameter analysis was used to determine the prognostic significance of each of the different , as shown in Figure 4A . We also analyzed the prognostic value of MTA1 expression in selective patient subgroups stratified according to the histopathologic type. In lung squamous cell carcinoma, patients with a high level of expression of MTA1 had a significantly shorter overall survival compared with patients with a low level of expression of MTA1 (n ϭ 44; log rank, p ϭ 0.022; Figure 4B ). In lung adenocarcinoma, although a trend that differences in prognosis between patients with low or high expression of MTA1 was found, there was no statistically significant difference (n ϭ 38; log rank, p ϭ 0.165; Figure 4C ). Thus, MTA1 might be a valuable prognostic marker for patients with lung squamous cell carcinoma.
Multivariate Analysis
To determine the smallest number of parameters that could jointly predict disease recurrence in our cohort of patients, the Cox proportional hazard model and stepwise selection anal- 
DISCUSSION
NSCLC is one of the most deadly human carcinomas even with improved diagnosis and compositive therapy, and the prognosis of NSCLC remains dismal. Metastasis is the major cause of treatment failure in patients with NSCLC. Its molecular mechanisms are still not clear and are under intensive investigations. So, exploring the relationship between novel gene functions and metastasis of lung cancer is important for enriching our understanding of the molecular mechanisms relative to progression of lung cancer, designing optimal medication, and improving the clinical prognosis of lung cancer.
MTA1, a novel candidate metastasis-associated gene, is known to increase the migration and invasion of various tumor cells in vitro. [23] [24] [25] Analysis of various tumor tissues have also found that overexpression of MTA1 mRNA or protein is correlated positively with the extent of tumor invasion or lymph node metastasis. 9 -15 We observed that MTA1 protein level in NSCLC samples were significantly higher than the level in their adjacent nonneoplastic lung tissues. The NSCLC overexpressing MTA1 protein showed higher rates of lymph node metastasis, and the MTA1 protein level was significantly higher in advanced lung cancer. The demonstrated correlation between MTA1 expression and lymph node metastasis, clinical stage is in accordance with one previous study by Sasaki et al. 26 These indicate that MTA1 might play an important role in the multistep process of carcinogenesis and progression of NSCLC, especially in tumor metastasis. MTA1 is a component of NuRD complexes. MTA1 can regulate gene transcription by recruiting histone deacetylase and thus plays its biologic effects. 7 In addition, MTA1 may inhibit p53-mediated apoptosis 27 and enhance the stability of hypoxia-inducible factor 1␣ with the result of promoting angiogenesis. 28 Our results also suggest that the development of NSCLC may be accompanied by upregulation of MTA1, but the mechanism of MTA1 upregulation is unclear.
Recently, researches have suggested that MTA1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma or breast cancer. 16, 17 Our Kaplan-Meier survival analysis also revealed that high-level MTA1 expression was significantly linked to a poor prognosis of patients with NSCLC after surgical resection. This finding may suggest the prognostic value of MTA1 expression for patients with NSCLC. It is obvious that the expression of MTA1 in NSCLC is inversely proportional to the survival time of patients with NSCLC. The higher the expression of MTA1 protein, the shorter the survival time for patients with NSCLC. However, although a significant correlation was found between MTA1 protein expression, lymph node metastasis, distant metastasis, or clinical stage and clinical outcome in our univariate analysis of survival rate, no such correlation was found in the multivariate analysis except local advance and clinical stage. So, MTA1 expression cannot be served as an independent predictor of prognosis for patients with NSCLC.
In summary, our study evaluated the prognostic significance of the MTA1 expression in a large number of NSCLC clinical tissue specimens at protein level by immunohistochemical analysis. The most valuable finding of this study is that the overall survival of our study cohort was significantly poorer in high-MTA1 expression cases than in low-MTA1 expression cases. In particular, MTA1 was significantly associated with poor prognosis in patients with lung squamous cell carcinoma.
We believe that further molecular, cellular, and animal model studies on MTA1 gene will provide new clues for exploring the mechanism of carcinogenesis and tumor progression in patients with NSCLC and blaze a new way in the gene-targeted therapy for lung cancer.
